Appendix 1

- Clinical and Laboratory Standards Institute M27.

Antifungal agentsSusceptibleSusceptible dose dependentIntermediateResistant
Fluconazole*≤816-32 ≥64
Itraconzole≤0.1250.25-0.5 ≥1
Flucytosine≤4 8-16≥32
Caspofungin≤2*   
Voriconazole<1  >4
  • * Candida krusei recovered from super infections have not been found to be susceptible to fluconazole and may require alternative antifungal therapy.

  • In clinical studies, voriconazole MIC90 for C. glabrata baseline was 4 ug/ml; 13/50 (26%). C. glabrata baseline isolates were resistant (MIC ≥4ug/ml) to voriconazole. However, based on 1054 isolates tested in surveillance studies the MIC90 was 1 ug/ml.